Joseph C. Fleishaker

Author

W.E. Upjohn Institute for Employment Research

Also Known As

J C Fleishaker, J FLEISHAKER, J Fleishaker, J. C. FLEISHAKER, J. C. Fleishaker, J.C Fleishaker, J.C. Fleishaker, Joseph C Fleishaker, Joseph C. Fleishaker, Joseph Fleishaker

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

W.E. Upjohn Institute for Employment Research American Pharmacists Association University of Kentucky

About

Joseph C. Fleishaker is an author at W.E. Upjohn Institute for Employment Research specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	28	1.1K
2	Health Sciences	4	4	153
3	Social Sciences	3	3	64
4	Engineering	2	2	63
5	Public Health	1	1	95

Joseph C. Fleishaker

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine Joseph C. Fleishaker, Laura K. Hulst European Journal of Clinical Pharmacology Psychoactive DrugPharmacological StudyCombined AdministrationMedicinePsychotropic Medication	1994	131
Factors Affecting the Milk-to-Plasma Drug Concentration Ratio in Lactating Women: Physical Interactions with Protein and Fat Joseph C. Fleishaker, Nirmala S. Desai, Patrick J. McNamara Journal of Pharmaceutical Sciences NutritionLactationMedicinePhysiologyPhysical Interactions	1987	117
Electrocardiographic Identification of Drug‐Induced QT Prolongation: Assessment by Different Recording and Measurement Methods Nenad Sarapa, Joel Morganroth, Jean‐Philippe Couderc, Annals of Noninvasive Electrocardiology PharmacotherapyManual DigipadMedical InstrumentationElectrophysiological EvaluationDrug‐induced Qt Prolongation	2004	95
Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine Todd Lasher, Joseph C. Fleishaker, Rick C. Steenwyk, Psychopharmacology Therapeutic Drug MonitoringPharmacological StudyCombined AdministrationMedicinePharmacotherapy	1991	95
Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Baltazar Gomez‐Mancilla, N.R. Cutler, M T Leibowitz, PubMed	2001	89
Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine Baltazar Gomez‐Mancilla, N.R. Cutler, M T Leibowitz, Cephalalgia Cluster HeadacheHealth SciencesAcute Migraine AttackPain MedicineMedicine	2001	83
Effect of age and gender on tirilazad pharmacokinetics in humans Laura K. Hulst, Joseph C. Fleishaker, Gary Peters, Clinical Pharmacology & Therapeutics	1994	73
Alprazolam absorption kinetics affects abuse liability* Geoffrey K. Mumford, Joseph C. Fleishaker, R. R. Griffiths Clinical Pharmacology & Therapeutics	1995	63
Phenytoin Causes a Rapid Increase in 6β‐Hydroxycortisol Urinary Excretion in Humans—A Putative Measure of CYP3A Induction Joseph C. Fleishaker, Laura Pearson, Gary Peters Journal of Pharmaceutical Sciences Molecular PharmacologyUrological ResearchUrologyUrinary ExcretionMedicine	1995	63
Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice Mark E. Cartwright, Steven E. Cohen, Joseph C. Fleishaker, Clinical Pharmacology & Therapeutics	2010	61

Page 1